Acumen Pharmaceuticals, Inc. ABOS
NASDAQ · United States · Health Technology
$2.07-0.15 (-6.76%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET. To participate in the live conference call, please register using this link. After registration
NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences. Cantor Global Healthcare Conference 2026 Date/Time: Fireside chat on Wednesday, September 9, 2026 at 3:55 p.m. ET Citi’s 2026 Biopharma Back to
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.